Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term adalimumab safety and tolerability in pediatric ulcerative colitis (extension of M11-290)
2023-504711-32-00Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 4
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in autoimmune colitis, sponsored by AbbVie Inc. Primary endpoint: Efficacy assessment by PMS, Mayo score, and PUCAI. Started Jan 2024; status: completed.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2023-504711-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504711-32-00.